ASX - By Stock
|
4DX |
Re:
Ann: 4DMedical secures $10m strategic investment from Pro Medicus
|
|
bedger
|
134 |
50K |
14 |
07/08/25 |
07/08/25 |
ASX - By Stock
|
134
|
50K
|
14
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Webinar
|
|
bedger
|
19 |
3.6K |
3 |
07/08/25 |
07/08/25 |
ASX - By Stock
|
19
|
3.6K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Webinar
|
|
bedger
|
19 |
3.6K |
4 |
06/08/25 |
06/08/25 |
ASX - By Stock
|
19
|
3.6K
|
4
|
|
ASX - By Stock
|
APX |
Re:
Ann: Q2 FY25 Quarterly Activity Report and Appendix 4C
|
|
bedger
|
162 |
52K |
1 |
06/08/25 |
06/08/25 |
ASX - By Stock
|
162
|
52K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Webinar
|
|
bedger
|
19 |
3.6K |
5 |
06/08/25 |
06/08/25 |
ASX - By Stock
|
19
|
3.6K
|
5
|
|
ASX - By Stock
|
APX |
Re:
Ann: Q2 FY25 Quarterly Activity Report and Appendix 4C
|
|
bedger
|
162 |
52K |
5 |
06/08/25 |
06/08/25 |
ASX - By Stock
|
162
|
52K
|
5
|
|
ASX - By Stock
|
APX |
Re:
Ann: Q2 FY25 Quarterly Activity Report and Appendix 4C
|
|
bedger
|
162 |
52K |
6 |
06/08/25 |
06/08/25 |
ASX - By Stock
|
162
|
52K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bedger
|
444 |
194K |
9 |
05/08/25 |
05/08/25 |
ASX - By Stock
|
444
|
194K
|
9
|
|
ASX - By Stock
|
4DX |
Re:
Ann: 4DMedical secures $10m strategic investment from Pro Medicus
|
|
bedger
|
134 |
50K |
10 |
05/08/25 |
05/08/25 |
ASX - By Stock
|
134
|
50K
|
10
|
|
ASX - By Stock
|
OCC |
Re:
Media thread
|
|
bedger
|
1.1K |
448K |
6 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
1.1K
|
448K
|
6
|
|
ASX - By Stock
|
OCC |
Re:
Ann: CelGro Facilitates Lymphatic Vessel Regeneration
|
|
bedger
|
43 |
15K |
5 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
43
|
15K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bedger
|
444 |
194K |
1 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
444
|
194K
|
1
|
|
ASX - By Stock
|
4DX |
Re:
Ann: 4DMedical secures $10m strategic investment from Pro Medicus
|
|
bedger
|
134 |
50K |
1 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
134
|
50K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bedger
|
32 |
7.5K |
2 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
32
|
7.5K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bedger
|
444 |
194K |
12 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
444
|
194K
|
12
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
bedger
|
32K |
16M |
7 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
32K
|
16M
|
7
|
|
ASX - By Stock
|
IMU |
Re:
Ann: 79% Overall Response Rate With Two Further Partial Responses
|
|
bedger
|
132 |
53K |
6 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
132
|
53K
|
6
|
|
ASX - By Stock
|
4DX |
Re:
Ann: 4DMedical secures $10m strategic investment from Pro Medicus
|
|
bedger
|
134 |
50K |
15 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
134
|
50K
|
15
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Activities Report June 2025 and Appendix 4C
|
|
bedger
|
10 |
2.1K |
1 |
02/08/25 |
02/08/25 |
ASX - By Stock
|
10
|
2.1K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: June 2025 Quarterly Activity Report and Appendix 4C
|
|
bedger
|
10 |
3.1K |
6 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
10
|
3.1K
|
6
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
bedger
|
32K |
16M |
17 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
32K
|
16M
|
17
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Loyalty and Piggyback Options Program
|
|
bedger
|
607 |
212K |
4 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
607
|
212K
|
4
|
|
ASX - By Stock
|
PNV |
Re:
Ann: FY25 Trading Result (unaudited)
|
|
bedger
|
215 |
68K |
2 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
215
|
68K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bedger
|
32 |
7.5K |
2 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
32
|
7.5K
|
2
|
|
ASX - By Stock
|
PNV |
Re:
Ann: FY25 Trading Result (unaudited)
|
|
bedger
|
215 |
68K |
14 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
215
|
68K
|
14
|
|
ASX - By Stock
|
CYP |
Re:
Ann: June 2025 Quarterly Activity Report and Appendix 4C
|
|
bedger
|
10 |
3.1K |
9 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
10
|
3.1K
|
9
|
|
ASX - By Stock
|
4DX |
Re:
Ann: 4DMedical secures $10m strategic investment from Pro Medicus
|
|
bedger
|
134 |
50K |
10 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
134
|
50K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Investor Webinar Presentation
|
|
bedger
|
74 |
22K |
29 |
31/07/25 |
31/07/25 |
ASX - By Stock
|
74
|
22K
|
29
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity successfully completes $203 million institutional pl
|
|
bedger
|
149 |
46K |
4 |
31/07/25 |
31/07/25 |
ASX - By Stock
|
149
|
46K
|
4
|
|
ASX - By Stock
|
APX |
Re:
Ann: Q2 FY25 Quarterly Activity Report and Appendix 4C
|
|
bedger
|
162 |
52K |
2 |
30/07/25 |
30/07/25 |
ASX - By Stock
|
162
|
52K
|
2
|
|
ASX - By Stock
|
PNV |
Re:
Ann: FY25 Trading Result (unaudited)
|
|
bedger
|
215 |
68K |
9 |
30/07/25 |
30/07/25 |
ASX - By Stock
|
215
|
68K
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Ann: CYP-001s FDA Approval Pathway Not Impeded
|
|
bedger
|
127 |
26K |
4 |
30/07/25 |
30/07/25 |
ASX - By Stock
|
127
|
26K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Change in substantial holding
|
|
bedger
|
14 |
4.0K |
1 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
14
|
4.0K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: CYP-001s FDA Approval Pathway Not Impeded
|
|
bedger
|
127 |
26K |
2 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
127
|
26K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: CYP-001s FDA Approval Pathway Not Impeded
|
|
bedger
|
127 |
26K |
2 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
127
|
26K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: CYP-001s FDA Approval Pathway Not Impeded
|
|
bedger
|
127 |
26K |
2 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
127
|
26K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: June 2025 Quarterly Activities Report & Appendix 4C
|
|
bedger
|
9 |
3.8K |
7 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
9
|
3.8K
|
7
|
|
ASX - By Stock
|
EYE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
bedger
|
44 |
11K |
8 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
44
|
11K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: CYP-001s FDA Approval Pathway Not Impeded
|
|
bedger
|
127 |
26K |
2 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
127
|
26K
|
2
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Business progress update, Zimmer Biomet sales units grows 3x
|
|
bedger
|
8 |
1.9K |
3 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
8
|
1.9K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Option Terms and Conditions
|
|
bedger
|
11 |
4.1K |
2 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
11
|
4.1K
|
2
|
|
ASX - By Stock
|
CYP Biotech |
Re:
CYP Price Target post MSB FDA approval.
|
|
bedger
|
380 |
112K |
3 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
380
|
112K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Completes $22.5M Placement and c.$15M SPP
|
|
bedger
|
233 |
79K |
4 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
233
|
79K
|
4
|
|
ASX - By Stock
|
4DX |
Re:
CT LVAS
|
|
bedger
|
14 |
5.4K |
6 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
14
|
5.4K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: CYP-001s FDA Approval Pathway Not Impeded
|
|
bedger
|
127 |
26K |
4 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
127
|
26K
|
4
|
|
ASX - By Stock
|
ASM |
Re:
Ann: Successful completion of Placement to raise A$13M
|
|
bedger
|
5 |
2.4K |
2 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
5
|
2.4K
|
2
|
|
ASX - By Stock
|
OCC |
Re:
Stem Cell Therapy advancements
|
|
bedger
|
491 |
189K |
2 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
491
|
189K
|
2
|
|
ASX - By Stock
|
OCC |
Re:
Stem Cell Therapy advancements
|
|
bedger
|
491 |
189K |
8 |
25/07/25 |
25/07/25 |
ASX - By Stock
|
491
|
189K
|
8
|
|
ASX - By Stock
|
CYP Biotech |
Re:
CYP Price Target post MSB FDA approval.
|
|
bedger
|
380 |
112K |
1 |
25/07/25 |
25/07/25 |
ASX - By Stock
|
380
|
112K
|
1
|
|
ASX - By Stock
|
CYP Biotech |
Re:
CYP Price Target post MSB FDA approval.
|
|
bedger
|
380 |
112K |
2 |
25/07/25 |
25/07/25 |
ASX - By Stock
|
380
|
112K
|
2
|
|